BISAMINOETHANETHIOL-TARGETING LIGAND CONJUGATES AND COMPOSITIONS
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
-
Citations
73 Claims
-
1-51. -51. (canceled)
-
52. A bis-aminoethanethiol (BAT)-targeting ligand conjugate, wherein the targeting ligand is an anticancer agent that is methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide tomudex, podophyllotoxin, mitoxantrone, camptothecin, colchicine, endostatin, fludarabin, gemcitabine, or tomudex;
- an agent that mimics glucose;
a folate receptor targeting ligand;
a DNA topoisomerase inhibitor;
a tumor apoptotic cell targeting ligand;
a tumor hypoxia targeting ligand that is annexin V, colchicine, nitroimidazole, mitomycin, or metronidazole;
or glutamate pentapeptide. - View Dependent Claims (53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)
- an agent that mimics glucose;
Specification